Co-Diagnostics holds special shareholder meeting
CODX•Co-Diagnostics shareholders approved a 2 million-share increase to the 2025 Equity Incentive Plan, raising its authorized share reserve to 2,223,333 shares. They also elected all five director nominees at the November 13, 2026, meeting.
1. Shareholders approve plan amendment
At its November 13, 2026, special meeting, Co-Diagnostics shareholders approved adding 2 million shares to the 2025 Equity Incentive Plan. The amendment took effect that day, increasing the authorized share reserve to 2,223,333 shares. Shareholders also elected all five director nominees.
